BMO Capital analyst Alex Arfaei reiterated a Market Perform rating and $90 price target on Eli Lilly (NYSE: LLY) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Piper Jaffray Cuts Price Target on Eli Lilly & Co. (LLY) Following Announced Discontinuation of Evacetrapib October 13, 2015 8:38 AM Eli Lilly's (LLY) Reaction to Disappointing Evacetrapib Data Appears 'Overdone', Says BofA/MLOctober 12, 2015 11:30 AM Eli Lilly's (LLY) Hold Rating Maintained at Deutsche Bank (MRK) (AMGN)October 12, 2015 10:14 AM Lilly's (LLY) CETP Inhibitor Disappointment Seen as Positive for Esperion (EPSR) and PCSK-9, Says RBC (REGN) (AMGN) (SNY) (MDCO) (MRK)October 12, 2015 9:13 AM UPDATE: Esperion (ESPR), Others Gains After Lilly Halts Development of Evacetrapib; Merch (MRK) FallsOctober 12, 2015 8:15 AM Eli Lilly & Co. (LLY) to Terminate Evacetrapib Development; Sees ChargesOctober 12, 2015 8:01 AM Eli Lilly & Co. (LLY) to Discontinue Development of EvacetrapibOctober 12, 2015 8:01 AM